Payment overview · 2025
General Payments
$1,436.34
64 reported records · 22 companies
Healthcare provider profile · identity verified
Victor E Herry
Allopathic & Osteopathic Physicians|Internal Medicine · CLINTON, MD · NPI 1073642625
Verified facts
What the public records show
CMS Open Payments records show Victor E Herry received $1,436.34 in general payments during 2025 across 64 reported records.
Amgen Inc. accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbyclor, Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Edarbyclor by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $207.51 | 14.4% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $177.79 | 12.4% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $148.81 | 10.4% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $110.92 | 7.7% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.95 | 5.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.17 | 5.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.59 | 5.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.49 | 4.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.96 | 4.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.46 | 4.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.51 | 3.7% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $48.94 | 3.4% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $44.47 | 3.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.63 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.72 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.89 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.96 | 1.8% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.89 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.79 | 1.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.38 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.89 | 1.1% | 1 | 2025 |
| Athena Bioscience, LLC | Unresolved — no canonical attribution shown | $15.62 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,436.34 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $146.36 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $143.96 | 7 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $124.68 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $110.92 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.61 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.07 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $92.61 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.59 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $62.46 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.51 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.39 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.39 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.83 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.83 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $48.94 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $44.47 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.63 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $31.43 | 2 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $25.89 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $24.13 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| NEXICLON XR Normalized: nexiclon xr |
Drug | Athena Bioscience, LLC | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBYCLOR edarbyclor |
2025 | Edarbyclor | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 75 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 31 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 425 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 68 |
| Losartan Potassium | Losartan Potassium | 176 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 57 |
| Simvastatin | Simvastatin | 156 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 51 |
| Metformin Hcl | Metformin Hcl | 149 | 54 |
| Carvedilol | Carvedilol | 148 | 53 |
| Azelastine Hcl | Azelastine Hcl | 145 | 84 |
| Lisinopril | Lisinopril | 137 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 47 |
| Nifedipine Er | Nifedipine | 130 | 46 |
| Gabapentin | Gabapentin | 112 | 49 |
| Allopurinol | Allopurinol | 109 | 36 |
| Furosemide | Furosemide | 108 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 35 |
| Farxiga | Dapagliflozin Propanediol | 89 | 31 |
| Potassium Chloride | Potassium Chloride | 88 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 24 |
| Eliquis | Apixaban | 75 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 29 |
| Januvia | Sitagliptin Phosphate | 73 | 20 |
| Trazodone Hcl | Trazodone Hcl | 73 | 36 |
| Montelukast Sodium | Montelukast Sodium | 66 | 24 |
| Ozempic | Semaglutide | 65 | 21 |
| Pregabalin | Pregabalin | 65 | 29 |
| Jardiance | Empagliflozin | 63 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 50 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 62 | 19 |
| Ibuprofen | Ibuprofen | 60 | 34 |
| Glimepiride | Glimepiride | 59 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 21 |
| Trulicity | Dulaglutide | 56 | 13 |
| Labetalol Hcl | Labetalol Hcl | 50 | 17 |
| Ezetimibe | Ezetimibe | 45 | 18 |
| Glipizide Er | Glipizide | 45 | 16 |
| Finasteride | Finasteride | 44 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 18 |
| Glipizide | Glipizide | 43 | 20 |
| Spironolactone | Spironolactone | 43 | 20 |
| Methocarbamol | Methocarbamol | 41 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | 16 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Omeprazole | Omeprazole | 38 | 22 |
| Prednisone | Prednisone | 38 | 21 |
| Sertraline Hcl | Sertraline Hcl | 38 | 17 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 15 |
| Mometasone Furoate | Mometasone Furoate | 35 | 22 |
| Methylprednisolone | Methylprednisolone | 34 | 30 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 33 | 12 |
| Azithromycin | Azithromycin | 33 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 14 |
| Telmisartan | Telmisartan | 31 | 11 |
| Lidocaine | Lidocaine | 30 | 13 |
| Clonidine Hcl | Clonidine Hcl | 29 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Colchicine | Colchicine | 28 | 13 |
| Chlorthalidone | Chlorthalidone | 27 | 12 |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Fluocinonide | Fluocinonide | 26 | 19 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Torsemide | Torsemide | 24 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Alprazolam | Alprazolam | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 20 | suppressed |
| Verapamil Sr | Verapamil Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,436.34 · 64 records | Amgen Inc. | AIRSUPRA, BodyGuardian, CDS - MCT/CEM Monitoring, Cologuard Collection Kit, EDARBYCLOR, ELIQUIS, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXICLON XR, NUCALA, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, Rhapsido, Rybelsus, STRENSIQ, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, VYEPTI, WAKIX, YUPELRI, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbyclor play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error